Ennaid Therapeutics partners with Strides to produce oral COVID‐19 tablet

Strides Pharma Science announced that its step‐down wholly-owned subsidiary, Strides Pharma Global Pte, Singapore has entered into an exclusive partnership with Ennaid Therapeutics, to produce an oral, repurposed medication to treat mild, moderate and asymptomatic cases of COVID‐19.

A company statement informed, “Ennaid’s partnership with discovery scientists at Universidad Católica de Murcia (UCAM) identified a therapeutic target to treat COVID‐19 using artificial intelligence drug discovery platforms. Initial tests show antiviral activity effective against SARS CoV‐2, the virus that causes COVID‐19, by inhibiting 90 per cent of the virus’ replication in vitro studies. These results are so compelling that Ennaid is ready to seek emergency authorisation from the FDA in the US as well as approval for compassionate use in India. Strides will be the exclusive manufacturing partner to Ennaid for the product.”